Alteration of this pathway occurs via mutations in oncogenes, such as the catalytic subunit of the class I PI3K (PIK3CA) or AKT1, in ~40% and ~7% of estrogen receptor positive (ER+) breast cancers, respectively4–7. The gene discussed is ESR1; the disease is breast carcinoma.